Selected research
Market Outlook & Growth Opportunities
Global Cell and Gene Therapy Services Market Outlook and Growth Opportunities 2026
Market perspective
The global Cell and Gene Therapy Services market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.
The North America market for Cell and Gene Therapy Services is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Cell and Gene Therapy Services is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Cell and Gene Therapy Services is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
In China, the Cell and Gene Therapy Services market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Major global companies in the Cell and Gene Therapy Services market include BioIT Solutions, Lonza, SK pharmteco, Hypertrust, Qiagen, Bio-Techne, Promega, Tenthpin and Thermo Fisher, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.
This report provides an overview of the global Cell and Gene Therapy Services market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Cell and Gene Therapy Services and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Cell and Gene Therapy Services revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Cell and Gene Therapy Services market.
Cell and Gene Therapy Services Segment by Company
BioIT Solutions
Lonza
SK pharmteco
Hypertrust
Qiagen
Bio-Techne
Promega
Tenthpin
Thermo Fisher
Charles River
ACROBiosystems
Revvity
Pharmaron
Cell and Gene Therapy Services Segment by Type
Gene Therapy
Cell Therapy
Cell and Gene Therapy Services Segment by Application
Hospital
Clinic
Cell and Gene Therapy Services Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global Cell and Gene Therapy Services status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the Cell and Gene Therapy Services key companies, revenue, market share, and recent developments.
3. To split the Cell and Gene Therapy Services breakdown data by regions, type, companies, and application.
4. To analyze the global and key regions Cell and Gene Therapy Services market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Cell and Gene Therapy Services significant trends, drivers, influence factors in global and regions.
6. To analyze Cell and Gene Therapy Services competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Cell and Gene Therapy Services market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Cell and Gene Therapy Services and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Cell and Gene Therapy Services.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size.
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Cell and Gene Therapy Services industry.
Chapter 3: Detailed analysis of Cell and Gene Therapy Services company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales value of Cell and Gene Therapy Services in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.
Chapter 7: Sales value of Cell and Gene Therapy Services in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 9: Concluding Insights.
More report detail
Tables and figures
Scope & coverage.
Types
- Gene Therapy
- Cell Therapy
Applications
- Hospital
- Clinic
Companies covered
- BioIT Solutions
- Lonza
- SK pharmteco
- Hypertrust
- Qiagen
- Bio-Techne
- Promega
- Tenthpin
- Thermo Fisher
- Charles River
- ACROBiosystems
- Revvity
- Pharmaron
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Cell and Gene Therapy Services Market Size, 2021 VS 2025 VS 2032
- 1.3 Global Cell and Gene Therapy Services Market Size (2021-2032)
- 1.4 Assumptions and Limitations
- 1.5 Study Goals and Objectives
2 Cell and Gene Therapy Services Market Dynamics
- 2.1 Cell and Gene Therapy Services Industry Trends
- 2.2 Cell and Gene Therapy Services Industry Drivers
- 2.3 Cell and Gene Therapy Services Industry Opportunities and Challenges
- 2.4 Cell and Gene Therapy Services Industry Restraints
3 Cell and Gene Therapy Services Market by Company
- 3.1 Global Cell and Gene Therapy Services Company Revenue Ranking in 2025
- 3.2 Global Cell and Gene Therapy Services Revenue by Company (2021-2026)
- 3.3 Global Cell and Gene Therapy Services Company Ranking (2024-2026)
- 3.4 Global Cell and Gene Therapy Services Company Manufacturing Base and Headquarters
- 3.5 Global Cell and Gene Therapy Services Company Product Type and Application
- 3.6 Global Cell and Gene Therapy Services Company Establishment Date
- 3.7 Market Competitive Analysis
- 3.7.1 Global Cell and Gene Therapy Services Market Concentration Ratio (CR5 and HHI)
- 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
- 3.7.3 2025 Cell and Gene Therapy Services Tier 1, Tier 2, and Tier 3 Companies
- 3.8 Mergers and Acquisitions Expansion
4 Cell and Gene Therapy Services Market by Type
- 4.1 Cell and Gene Therapy Services Type Introduction
- 4.1.1 Gene Therapy
- 4.1.2 Cell Therapy
- 4.2 Global Cell and Gene Therapy Services Sales Value by Type
- 4.2.1 Global Cell and Gene Therapy Services Sales Value by Type (2021 VS 2025 VS 2032)
- 4.2.2 Global Cell and Gene Therapy Services Sales Value by Type (2021-2032)
- 4.2.3 Global Cell and Gene Therapy Services Sales Value Share by Type (2021-2032)
5 Cell and Gene Therapy Services Market by Application
- 5.1 Cell and Gene Therapy Services Application Introduction
- 5.1.1 Hospital
- 5.1.2 Clinic
- 5.2 Global Cell and Gene Therapy Services Sales Value by Application
- 5.2.1 Global Cell and Gene Therapy Services Sales Value by Application (2021 VS 2025 VS 2032)
- 5.2.2 Global Cell and Gene Therapy Services Sales Value by Application (2021-2032)
- 5.2.3 Global Cell and Gene Therapy Services Sales Value Share by Application (2021-2032)
6 Cell and Gene Therapy Services Regional Value Analysis
- 6.1 Global Cell and Gene Therapy Services Sales Value by Region: 2021 VS 2025 VS 2032
- 6.2 Global Cell and Gene Therapy Services Sales Value by Region (2021-2032)
- 6.2.1 Global Cell and Gene Therapy Services Sales Value by Region: 2021-2026
- 6.2.2 Global Cell and Gene Therapy Services Sales Value by Region (2027-2032)
- 6.3 North America
- 6.3.1 North America Cell and Gene Therapy Services Sales Value (2021-2032)
- 6.3.2 North America Cell and Gene Therapy Services Sales Value Share by Country, 2025 VS 2032
- 6.4 Europe
- 6.4.1 Europe Cell and Gene Therapy Services Sales Value (2021-2032)
- 6.4.2 Europe Cell and Gene Therapy Services Sales Value Share by Country, 2025 VS 2032
- 6.5 Asia-Pacific
- 6.5.1 Asia-Pacific Cell and Gene Therapy Services Sales Value (2021-2032)
- 6.5.2 Asia-Pacific Cell and Gene Therapy Services Sales Value Share by Country, 2025 VS 2032
- 6.6 South America
- 6.6.1 South America Cell and Gene Therapy Services Sales Value (2021-2032)
- 6.6.2 South America Cell and Gene Therapy Services Sales Value Share by Country, 2025 VS 2032
- 6.7 Middle East & Africa
- 6.7.1 Middle East & Africa Cell and Gene Therapy Services Sales Value (2021-2032)
- 6.7.2 Middle East & Africa Cell and Gene Therapy Services Sales Value Share by Country, 2025 VS 2032
7 Cell and Gene Therapy Services Country-level Value Analysis
- 7.1 Global Cell and Gene Therapy Services Sales Value by Country: 2021 VS 2025 VS 2032
- 7.2 Global Cell and Gene Therapy Services Sales Value by Country (2021-2032)
- 7.2.1 Global Cell and Gene Therapy Services Sales Value by Country (2021-2026)
- 7.2.2 Global Cell and Gene Therapy Services Sales Value by Country (2027-2032)
- 7.3 USA
- 7.3.1 USA Cell and Gene Therapy Services Sales Value Growth Rate (2021-2032)
- 7.3.2 USA Cell and Gene Therapy Services Sales Value Share by Type, 2025 VS 2032
- 7.3.3 USA Cell and Gene Therapy Services Sales Value Share by Application, 2025 VS 2032
- 7.4 Canada
- 7.4.1 Canada Cell and Gene Therapy Services Sales Value Growth Rate (2021-2032)
- 7.4.2 Canada Cell and Gene Therapy Services Sales Value Share by Type, 2025 VS 2032
- 7.4.3 Canada Cell and Gene Therapy Services Sales Value Share by Application, 2025 VS 2032
- 7.5 Mexico
- 7.5.1 Mexico Cell and Gene Therapy Services Sales Value Growth Rate (2021-2032)
- 7.5.2 Mexico Cell and Gene Therapy Services Sales Value Share by Type, 2025 VS 2032
- 7.5.3 Mexico Cell and Gene Therapy Services Sales Value Share by Application, 2025 VS 2032
- 7.6 Germany
- 7.6.1 Germany Cell and Gene Therapy Services Sales Value Growth Rate (2021-2032)
- 7.6.2 Germany Cell and Gene Therapy Services Sales Value Share by Type, 2025 VS 2032
- 7.6.3 Germany Cell and Gene Therapy Services Sales Value Share by Application, 2025 VS 2032
- 7.7 France
- 7.7.1 France Cell and Gene Therapy Services Sales Value Growth Rate (2021-2032)
- 7.7.2 France Cell and Gene Therapy Services Sales Value Share by Type, 2025 VS 2032
- 7.7.3 France Cell and Gene Therapy Services Sales Value Share by Application, 2025 VS 2032
- 7.8 U.K.
- 7.8.1 U.K. Cell and Gene Therapy Services Sales Value Growth Rate (2021-2032)
- 7.8.2 U.K. Cell and Gene Therapy Services Sales Value Share by Type, 2025 VS 2032
- 7.8.3 U.K. Cell and Gene Therapy Services Sales Value Share by Application, 2025 VS 2032
- 7.9 Italy
- 7.9.1 Italy Cell and Gene Therapy Services Sales Value Growth Rate (2021-2032)
- 7.9.2 Italy Cell and Gene Therapy Services Sales Value Share by Type, 2025 VS 2032
- 7.9.3 Italy Cell and Gene Therapy Services Sales Value Share by Application, 2025 VS 2032
- 7.10 Spain
- 7.10.1 Spain Cell and Gene Therapy Services Sales Value Growth Rate (2021-2032)
- 7.10.2 Spain Cell and Gene Therapy Services Sales Value Share by Type, 2025 VS 2032
- 7.10.3 Spain Cell and Gene Therapy Services Sales Value Share by Application, 2025 VS 2032
- 7.11 Russia
- 7.11.1 Russia Cell and Gene Therapy Services Sales Value Growth Rate (2021-2032)
- 7.11.2 Russia Cell and Gene Therapy Services Sales Value Share by Type, 2025 VS 2032
- 7.11.3 Russia Cell and Gene Therapy Services Sales Value Share by Application, 2025 VS 2032
- 7.12 Netherlands
- 7.12.1 Netherlands Cell and Gene Therapy Services Sales Value Growth Rate (2021-2032)
- 7.12.2 Netherlands Cell and Gene Therapy Services Sales Value Share by Type, 2025 VS 2032
- 7.12.3 Netherlands Cell and Gene Therapy Services Sales Value Share by Application, 2025 VS 2032
- 7.13 Nordic Countries
- 7.13.1 Nordic Countries Cell and Gene Therapy Services Sales Value Growth Rate (2021-2032)
- 7.13.2 Nordic Countries Cell and Gene Therapy Services Sales Value Share by Type, 2025 VS 2032
- 7.13.3 Nordic Countries Cell and Gene Therapy Services Sales Value Share by Application, 2025 VS 2032
- 7.14 China
- 7.14.1 China Cell and Gene Therapy Services Sales Value Growth Rate (2021-2032)
- 7.14.2 China Cell and Gene Therapy Services Sales Value Share by Type, 2025 VS 2032
- 7.14.3 China Cell and Gene Therapy Services Sales Value Share by Application, 2025 VS 2032
- 7.15 Japan
- 7.15.1 Japan Cell and Gene Therapy Services Sales Value Growth Rate (2021-2032)
- 7.15.2 Japan Cell and Gene Therapy Services Sales Value Share by Type, 2025 VS 2032
- 7.15.3 Japan Cell and Gene Therapy Services Sales Value Share by Application, 2025 VS 2032
- 7.16 South Korea
- 7.16.1 South Korea Cell and Gene Therapy Services Sales Value Growth Rate (2021-2032)
- 7.16.2 South Korea Cell and Gene Therapy Services Sales Value Share by Type, 2025 VS 2032
- 7.16.3 South Korea Cell and Gene Therapy Services Sales Value Share by Application, 2025 VS 2032
- 7.17 India
- 7.17.1 India Cell and Gene Therapy Services Sales Value Growth Rate (2021-2032)
- 7.17.2 India Cell and Gene Therapy Services Sales Value Share by Type, 2025 VS 2032
- 7.17.3 India Cell and Gene Therapy Services Sales Value Share by Application, 2025 VS 2032
- 7.18 Australia
- 7.18.1 Australia Cell and Gene Therapy Services Sales Value Growth Rate (2021-2032)
- 7.18.2 Australia Cell and Gene Therapy Services Sales Value Share by Type, 2025 VS 2032
- 7.18.3 Australia Cell and Gene Therapy Services Sales Value Share by Application, 2025 VS 2032
- 7.19 Southeast Asia
- 7.19.1 Southeast Asia Cell and Gene Therapy Services Sales Value Growth Rate (2021-2032)
- 7.19.2 Southeast Asia Cell and Gene Therapy Services Sales Value Share by Type, 2025 VS 2032
- 7.19.3 Southeast Asia Cell and Gene Therapy Services Sales Value Share by Application, 2025 VS 2032
- 7.20 Brazil
- 7.20.1 Brazil Cell and Gene Therapy Services Sales Value Growth Rate (2021-2032)
- 7.20.2 Brazil Cell and Gene Therapy Services Sales Value Share by Type, 2025 VS 2032
- 7.20.3 Brazil Cell and Gene Therapy Services Sales Value Share by Application, 2025 VS 2032
- 7.21 Argentina
- 7.21.1 Argentina Cell and Gene Therapy Services Sales Value Growth Rate (2021-2032)
- 7.21.2 Argentina Cell and Gene Therapy Services Sales Value Share by Type, 2025 VS 2032
- 7.21.3 Argentina Cell and Gene Therapy Services Sales Value Share by Application, 2025 VS 2032
- 7.22 Chile
- 7.22.1 Chile Cell and Gene Therapy Services Sales Value Growth Rate (2021-2032)
- 7.22.2 Chile Cell and Gene Therapy Services Sales Value Share by Type, 2025 VS 2032
- 7.22.3 Chile Cell and Gene Therapy Services Sales Value Share by Application, 2025 VS 2032
- 7.23 Colombia
- 7.23.1 Colombia Cell and Gene Therapy Services Sales Value Growth Rate (2021-2032)
- 7.23.2 Colombia Cell and Gene Therapy Services Sales Value Share by Type, 2025 VS 2032
- 7.23.3 Colombia Cell and Gene Therapy Services Sales Value Share by Application, 2025 VS 2032
- 7.24 Peru
- 7.24.1 Peru Cell and Gene Therapy Services Sales Value Growth Rate (2021-2032)
- 7.24.2 Peru Cell and Gene Therapy Services Sales Value Share by Type, 2025 VS 2032
- 7.24.3 Peru Cell and Gene Therapy Services Sales Value Share by Application, 2025 VS 2032
- 7.25 Saudi Arabia
- 7.25.1 Saudi Arabia Cell and Gene Therapy Services Sales Value Growth Rate (2021-2032)
- 7.25.2 Saudi Arabia Cell and Gene Therapy Services Sales Value Share by Type, 2025 VS 2032
- 7.25.3 Saudi Arabia Cell and Gene Therapy Services Sales Value Share by Application, 2025 VS 2032
- 7.26 Israel
- 7.26.1 Israel Cell and Gene Therapy Services Sales Value Growth Rate (2021-2032)
- 7.26.2 Israel Cell and Gene Therapy Services Sales Value Share by Type, 2025 VS 2032
- 7.26.3 Israel Cell and Gene Therapy Services Sales Value Share by Application, 2025 VS 2032
- 7.27 UAE
- 7.27.1 UAE Cell and Gene Therapy Services Sales Value Growth Rate (2021-2032)
- 7.27.2 UAE Cell and Gene Therapy Services Sales Value Share by Type, 2025 VS 2032
- 7.27.3 UAE Cell and Gene Therapy Services Sales Value Share by Application, 2025 VS 2032
- 7.28 Turkey
- 7.28.1 Turkey Cell and Gene Therapy Services Sales Value Growth Rate (2021-2032)
- 7.28.2 Turkey Cell and Gene Therapy Services Sales Value Share by Type, 2025 VS 2032
- 7.28.3 Turkey Cell and Gene Therapy Services Sales Value Share by Application, 2025 VS 2032
- 7.29 Iran
- 7.29.1 Iran Cell and Gene Therapy Services Sales Value Growth Rate (2021-2032)
- 7.29.2 Iran Cell and Gene Therapy Services Sales Value Share by Type, 2025 VS 2032
- 7.29.3 Iran Cell and Gene Therapy Services Sales Value Share by Application, 2025 VS 2032
- 7.30 Egypt
- 7.30.1 Egypt Cell and Gene Therapy Services Sales Value Growth Rate (2021-2032)
- 7.30.2 Egypt Cell and Gene Therapy Services Sales Value Share by Type, 2025 VS 2032
- 7.30.3 Egypt Cell and Gene Therapy Services Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
- 8.1 BioIT Solutions
- 8.1.1 BioIT Solutions Company Information
- 8.1.2 BioIT Solutions Business Overview
- 8.1.3 BioIT Solutions Cell and Gene Therapy Services Revenue and Gross Margin (2021-2026)
- 8.1.4 BioIT Solutions Cell and Gene Therapy Services Product Portfolio
- 8.1.5 BioIT Solutions Recent Developments
- 8.2 Lonza
- 8.2.1 Lonza Company Information
- 8.2.2 Lonza Business Overview
- 8.2.3 Lonza Cell and Gene Therapy Services Revenue and Gross Margin (2021-2026)
- 8.2.4 Lonza Cell and Gene Therapy Services Product Portfolio
- 8.2.5 Lonza Recent Developments
- 8.3 SK pharmteco
- 8.3.1 SK pharmteco Company Information
- 8.3.2 SK pharmteco Business Overview
- 8.3.3 SK pharmteco Cell and Gene Therapy Services Revenue and Gross Margin (2021-2026)
- 8.3.4 SK pharmteco Cell and Gene Therapy Services Product Portfolio
- 8.3.5 SK pharmteco Recent Developments
- 8.4 Hypertrust
- 8.4.1 Hypertrust Company Information
- 8.4.2 Hypertrust Business Overview
- 8.4.3 Hypertrust Cell and Gene Therapy Services Revenue and Gross Margin (2021-2026)
- 8.4.4 Hypertrust Cell and Gene Therapy Services Product Portfolio
- 8.4.5 Hypertrust Recent Developments
- 8.5 Qiagen
- 8.5.1 Qiagen Company Information
- 8.5.2 Qiagen Business Overview
- 8.5.3 Qiagen Cell and Gene Therapy Services Revenue and Gross Margin (2021-2026)
- 8.5.4 Qiagen Cell and Gene Therapy Services Product Portfolio
- 8.5.5 Qiagen Recent Developments
- 8.6 Bio-Techne
- 8.6.1 Bio-Techne Company Information
- 8.6.2 Bio-Techne Business Overview
- 8.6.3 Bio-Techne Cell and Gene Therapy Services Revenue and Gross Margin (2021-2026)
- 8.6.4 Bio-Techne Cell and Gene Therapy Services Product Portfolio
- 8.6.5 Bio-Techne Recent Developments
- 8.7 Promega
- 8.7.1 Promega Company Information
- 8.7.2 Promega Business Overview
- 8.7.3 Promega Cell and Gene Therapy Services Revenue and Gross Margin (2021-2026)
- 8.7.4 Promega Cell and Gene Therapy Services Product Portfolio
- 8.7.5 Promega Recent Developments
- 8.8 Tenthpin
- 8.8.1 Tenthpin Company Information
- 8.8.2 Tenthpin Business Overview
- 8.8.3 Tenthpin Cell and Gene Therapy Services Revenue and Gross Margin (2021-2026)
- 8.8.4 Tenthpin Cell and Gene Therapy Services Product Portfolio
- 8.8.5 Tenthpin Recent Developments
- 8.9 Thermo Fisher
- 8.9.1 Thermo Fisher Company Information
- 8.9.2 Thermo Fisher Business Overview
- 8.9.3 Thermo Fisher Cell and Gene Therapy Services Revenue and Gross Margin (2021-2026)
- 8.9.4 Thermo Fisher Cell and Gene Therapy Services Product Portfolio
- 8.9.5 Thermo Fisher Recent Developments
- 8.10 Charles River
- 8.10.1 Charles River Company Information
- 8.10.2 Charles River Business Overview
- 8.10.3 Charles River Cell and Gene Therapy Services Revenue and Gross Margin (2021-2026)
- 8.10.4 Charles River Cell and Gene Therapy Services Product Portfolio
- 8.10.5 Charles River Recent Developments
- 8.11 ACROBiosystems
- 8.11.1 ACROBiosystems Company Information
- 8.11.2 ACROBiosystems Business Overview
- 8.11.3 ACROBiosystems Cell and Gene Therapy Services Revenue and Gross Margin (2021-2026)
- 8.11.4 ACROBiosystems Cell and Gene Therapy Services Product Portfolio
- 8.11.5 ACROBiosystems Recent Developments
- 8.12 Revvity
- 8.12.1 Revvity Company Information
- 8.12.2 Revvity Business Overview
- 8.12.3 Revvity Cell and Gene Therapy Services Revenue and Gross Margin (2021-2026)
- 8.12.4 Revvity Cell and Gene Therapy Services Product Portfolio
- 8.12.5 Revvity Recent Developments
- 8.13 Pharmaron
- 8.13.1 Pharmaron Company Information
- 8.13.2 Pharmaron Business Overview
- 8.13.3 Pharmaron Cell and Gene Therapy Services Revenue and Gross Margin (2021-2026)
- 8.13.4 Pharmaron Cell and Gene Therapy Services Product Portfolio
- 8.13.5 Pharmaron Recent Developments
9 Concluding Insights
10 Appendix
- 10.1 Reasons for Doing This Study
- 10.2 Research Methodology
- 10.3 Research Process
- 10.4 Authors List of This Report
- 10.5 Data Source
- 10.5.1 Secondary Sources
- 10.5.2 Primary Sources
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst